Vyriad
Pre-clinicalVyriad engineers targeted virus platforms that bring durable in vivo gene therapies, genome editing, and oncolytic virotherapies to patients.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $47.5M
About
Vyriad engineers targeted virus platforms that bring durable in vivo gene therapies, genome editing, and oncolytic virotherapies to patients.
Viral Technology
Funding History
3Total raised:$47.5M
Grant$2.5MApr 15, 2020
Series B$30MJun 15, 2019
Series A$15MOct 15, 2017